Cargando...
Heregulin induces resistance to lapatinib‐mediated growth inhibition of HER2‐amplified cancer cells
Human epidermal growth factor receptor 2 (HER2) amplification occurs in approximately 20% of gastric and gastroesophageal junction cancers in the United States and European Union. Lapatinib, a dual HER2 and epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated clinical efficac...
Gardado en:
| Publicado en: | Cancer Sci |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7653524/ https://ncbi.nlm.nih.gov/pubmed/24112719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12290 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|